SGLT-2 inhibitors and most GLP-1 receptor agonists demonstrated cardiovascular superiority and reduction of cardiovascular and overall mortality. These results stand as a turning point in the management of diabetes, shifting the focus from controlling glucose levels to mastering the extra-glycemic effects of these new drugs. This narrative review will discuss recent CVOT with focus on SGLT-2 inhibitors and GLP-1 receptor agonists to distinguish relevant patients' characteristics as potential predictors for therapeutic efficacy. It will also examine their efficacy and safety, the differences in their cardiovascular and renal benefits, aiming to convey clinical suggestions for everyday practice.

中文翻译：

---

在已建立的动脉粥样硬化性心脏病或有充血性心力衰竭风险的患者中，SGLT-2抑制剂与GLP-1受体激动剂的鉴别适应症。

SGLT-2抑制剂和大多数GLP-1受体激动剂显示出心血管优越性，并降低了心血管和整体死亡率。这些结果成为糖尿病治疗的转折点，将重点从控制葡萄糖水平转移到掌握这些新药的降血糖作用。这篇叙述性评论将讨论最近的CVOT，重点是SGLT-2抑制剂和GLP-1受体激动剂，以区分相关患者的特征作为治疗效果的潜在预测指标。它还将检查它们的功效和安全性，它们在心血管和肾脏益处方面的差异，旨在传达日常实践的临床建议。